Jefferies Group's TSHA Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 479,000 shares of Taysha Gene Therapies, Inc. (TSHA) worth $2.14 M, representing 0.01% of the portfolio. First purchased in 2024-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in TSHA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 10.07 M shares. Largest reduction occurred in Q3 2025, reducing 8.16 M shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Taysha Gene Therapies (TSHA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Taysha Gene Therapies (TSHA) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +454,000 | Add 1816.00% | 479,000 | $4.47 |
| Q4 2025 | -2.13 M | Reduce 98.84% | 25,000 | $5.50 |
| Q3 2025 | -8.16 M | Reduce 79.09% | 2.16 M | $3.27 |
| Q2 2025 | +10.07 M | Add 4105.33% | 10.31 M | $2.31 |
| Q1 2025 | +245,254 | New Buy | 245,254 | $1.39 |
| Q4 2024 | -73,857 | Sold Out | 0 | $0.00 |
| Q3 2024 | -183,837 | Reduce 71.34% | 73,857 | $2.01 |
| Q2 2024 | +209,594 | Add 435.75% | 257,694 | $2.24 |
| Q1 2024 | +48,100 | New Buy | 48,100 | $2.87 |
Jefferies Group's Taysha Gene Therapies Investment FAQs
Jefferies Group first purchased Taysha Gene Therapies, Inc. (TSHA) in Q1 2024, acquiring 48,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Taysha Gene Therapies, Inc. (TSHA) for 9 quarters since Q1 2024.
Jefferies Group's largest addition to Taysha Gene Therapies, Inc. (TSHA) was in Q2 2025, adding 10,313,733 shares worth $23.82 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 479,000 shares of Taysha Gene Therapies, Inc. (TSHA), valued at approximately $2.14 M.
As of the Q1 2026 filing, Taysha Gene Therapies, Inc. (TSHA) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Taysha Gene Therapies, Inc. (TSHA) was 10,313,733 shares, as reported at the end of Q2 2025.